{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:06:08Z","timestamp":1790193968445,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008426","name":"Friedrich-Baur-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.rmed.2024.107868","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:34:35Z","timestamp":1732023275000},"page":"107868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor before, during, and after pregnancy in women with cystic fibrosis: An observational study"],"prefix":"10.1016","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-8350","authenticated-orcid":false,"given":"Christina","family":"Shad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8831-0238","authenticated-orcid":false,"given":"Michael","family":"Paal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-346X","authenticated-orcid":false,"given":"Katharina","family":"Habler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Breuling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-6687","authenticated-orcid":false,"given":"Christiane","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Naehrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.rmed.2024.107868_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rmed.2024.107868_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00404-023-06962-5","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor combination in pregnancy","volume":"309","author":"Cimino","year":"2024","journal-title":"Arch. Gynecol. Obstet."},{"issue":"9","key":"10.1016\/j.rmed.2024.107868_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090928","article-title":"State of the art on approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators and triple-combination therapy","volume":"14","author":"Meoli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.rmed.2024.107868_bib5","volume":"vols. 1\u201347","year":"2020"},{"issue":"19","key":"10.1016\/j.rmed.2024.107868_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.rmed.2024.107868_bib7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.rmed.2024.107868_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041468","article-title":"Pregnancy in cystic fibrosis-past, present, and future","volume":"12","author":"Gur","year":"2023","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.rmed.2024.107868_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092706","article-title":"Impact on fertility, pregnancy, and lactation in women with cystic fibrosis","volume":"9","author":"Taylor-Cousar","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.rmed.2024.107868_bib10","series-title":"2022 Patient Registry Annual Data Report","year":"2023"},{"key":"10.1016\/j.rmed.2024.107868_bib11","series-title":"UK Cystic Fibrosis Registry 2022 Annual Data Report","year":"2023"},{"key":"10.1016\/j.rmed.2024.107868_bib12","series-title":"Vertex Pharmaceuticals Incorporated: Boston","year":"2019"},{"issue":"3","key":"10.1016\/j.rmed.2024.107868_bib13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2024.107868_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.rmed.2024.107868_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"8","key":"10.1016\/j.rmed.2024.107868_bib16","article-title":"Cystic fibrosis transmembrane conductance regulator modulators during pregnancy: a case series","volume":"13","author":"Kendle","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.rmed.2024.107868_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01208-2019","article-title":"ERS\/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases","volume":"55","author":"Middleton","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.rmed.2024.107868_bib18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/jpm14101065","article-title":"Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor in adult people with cystic fibrosis","volume":"14","author":"Naehrig","year":"2024","journal-title":"J. Personalized Med."},{"issue":"8","key":"10.1016\/j.rmed.2024.107868_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.rmed.2024.107868_bib20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2024.107868_bib21","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S1569-1993(23)00435-6","article-title":"P060 Measurement of the plasma concentration of elexacaftor\/tezacaftor\/ivacaftor (ETI) by LC\/MS-MS in a patient with cystic fibrosis during pregnancy","volume":"22","author":"Mattei","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2024.107868_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1274303","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","volume":"10","author":"Ripani","year":"2023","journal-title":"Front. Med."},{"issue":"8","key":"10.1016\/j.rmed.2024.107868_bib23","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.rmed.2024.107868_bib24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2024.107868_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1515\/cclm-2021-0724","article-title":"Isotope dilution LC-MS\/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum","volume":"60","author":"Habler","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.rmed.2024.107868_bib26","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"5","key":"10.1016\/j.rmed.2024.107868_bib27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1021\/acsptsci.0c00098","article-title":"The balance between the safety of mother, fetus, and newborn undergoing cystic fibrosis transmembrane conductance regulator treatments during pregnancy","volume":"3","author":"Qiu","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.rmed.2024.107868_bib28","year":"2019","journal-title":"Multi-Discipline Review Trikafta (Elexacaftor\/Tezacaftor\/Ivacaftor)"},{"issue":"6","key":"10.1016\/j.rmed.2024.107868_bib29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2024.107868_bib30","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jcf.2019.12.004","article-title":"To be or not to be on CFTR modulators during pregnancy: risks to be considered","volume":"19","author":"Vekaria","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2024.107868_bib31","article-title":"Comparison of two pregnancies with and without elexacaftor-tezacaftor-ivacaftor in a woman with cystic fibrosis","volume":"83","author":"Chamagne","year":"2023","journal-title":"Respir Med Res"},{"key":"10.1016\/j.rmed.2024.107868_bib32","first-page":"S32","article-title":"53 Pregnancies in women with cystic fibrosis with or without intake of elexacaftor\/tezacaftor\/ivacaftor","volume":"21","author":"Naehrig","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"17","key":"10.1016\/j.rmed.2024.107868_bib33","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2024.107868_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00404-023-06962-5","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor combination in pregnancy","volume":"309","author":"Cimino","year":"2024","journal-title":"Arch. Gynecol. Obstet."},{"issue":"6","key":"10.1016\/j.rmed.2024.107868_bib35","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J. Cyst. Fibros."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124003433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124003433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T22:01:16Z","timestamp":1738879276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611124003433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"alternative-id":["S0954611124003433"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107868","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor before, during, and after pregnancy in women with cystic fibrosis: An observational study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107868"}}